Infectious Diseases

  • 20 November 2018
    News

    Roivant and iNtRON sign licensing deal for SAL200

    Roivant Sciences and iNtRON Biotechnology have signed a $667.5m global licensing agreement for SAL200, which is an investigational biologic to treat infectious diseases caused by antibiotic-resistant staphylococci.

Close
Close
Close

Go Top